Results and data from a U.S. study originally conducted between 1999 and 2002 have recently been published….
The study population included 7,109 people with type 2 diabetes from 8 health plans participating in the Translating Research Into Action for Diabetes (TRIAD).
Results from the study revealed that the mean annualized direct medical cost was $2,465 for a Caucasian men with type 2 diabetes who had been diagnosed fewer than 15 years earlier, had previously been treated with oral medication or diet alone and had existing complications or comorbidities in the present time.
The researchers discovered annualized medical costs to be 10% to 50% more expansive for women and for patients whose diabetes had been diagnosed 15 or more years earlier, who used tobacco, who were being actively treated with insulin, or who were positive for several other diabetic related complications. Diabetic comorbidities such as: coronary heart disease, congestive heart failure, hemiplegia and amputation were each associated with an increase in cost of approximately 70% to 150%. End-stage renal disease and treatment with dialysis were associated with approximately a 300% higher cost compared to a diabetic patient without any complications. Patients with end-stage renal disease who require a kidney transplant can expect to pay approximately more 500% higher costs than a normal diabetic patient without complications.
In conclusion, the researchers found that most medical expanses for type 2 diabetics accumulate when comorbidities and complications arise.
The American Journal of Managed Care, 05/28/2013